Objectives & Accreditation
Total Page:16
File Type:pdf, Size:1020Kb
Objectives & Accreditation ACTIVITY FORMAT Live TARGET AUDIENCE This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, nurse practitioners, advance practice registered nurses, and registered dietitians with an interest in lipid management. TYPE OF ACTIVITY Live Activity; Application/ Knowledge EDUCATIONAL OBJECTIVES At the conclusion of this activity, Registered Nurses and Nurse Practitioners should be able to provide appropriate care and counsel for patients and their families. At the conclusion of this activity, all participants should be able to: Session I: The Impact of Genetics in Lipidology? Apply insight from human population genetics studies to identify novel therapeutic targets for a better understanding for atherosclerotic cardiovascular disease. Describe the current and future technologies available for genetic screen includinghow to apply them in clinical practice both for diagnosis and risk assessment Discuss experimental techniques in development for genetic manipulation to target inherited lipid disorders Keynote I Discuss ApoC3 as both a risk factor for ASCVD and as potential for therapeutic manipulation Session II- Focus on Lipoprotein (a) Discuss the epidemiology of Lipoprotein(a) (LP(a)) for both thrombosis and ASCVD Discuss the pathophysiology of LP(a) and how this impacts increased risk of ASCVD and thrombosis Discuss the status of current and emerging treatment options targeting LP(a) Clinical Lipidology Track- Critically appraise emerging research and its applications to daily clinical practice Discuss the diagnosis and treatment of genetic hypertriglyceridemia Describe the approach to diagnosis and therapeutic interventions available to manage uncommon dyslipidemias with common clinical presentations Discuss the clinically relevant drug and non-drug interactions of lipid lowering drugs Basic Science Track- Critically appraise emerging research and its applications to daily clinical practice Describe the impact of the intestinal microbiome on lipid, lipoproteins, and risk for ASCVD Discuss new and emerging treatment for triglyceride biology Discuss new and emerging treatment for HDL biology Discuss evidence regarding hepatic lipase and its impact on ApoC3 and lipoprotein biology Keynote II Discuss novel concepts in fatty liver disease Session III- Updates in Lipid Therapeutics Describe the efficacy, safety, and mechanisms of action of novel lipid-targeted pharmacotherapies Examine the data on safety and efficacy of therapies that target proprotein convertase subtilisin/kexin type 9 (PCSK9) Discuss the clinical application of coronary calcium scores Session IV- Updates in Lipid Recommendations Discuss Canadian lipid screening and other strategies in children in reducing cardiovascular risk Demonstrate the practical application of the NLA Annual Summary to the clinical evaluation and management of patients with dyslipidemia Discuss current guidelines & recommendations on the diagnosis, management, & treatment of dyslipidemia Session V- Familial Hypercholesterolemia (FH)- Where do we go from here? Outline European guidelines and recommendations for managing Patients with HoFH Illustrate the importance of universal screening during childhood and cascade lipid screening of family members of known FH patients. Discuss the importance of genetic testing and clinical care for a patient with FH. Keynote III Discuss the potential role of applications in optimizing lipid management Session VI- HIV/ AIDS Discuss atherosclerosis in patients with HIV. Differentiate the factors that lead to residual risk in the patient with HIV Apply lipid-lowering treatment strategies in patients with HIV Session VI- Women's Health Compare and contrast available risk assessment algorithms (including FRS, ACC/AHA CV Risk Calculator, Reynolds Risk Score, new MESA algorithm) and their accuracy (over- and underestimation) in women Appraise treatment recommendations and evidence for screening, diagnosing and treating FH during pregnancy Describe the impacts of various forms of oral contraception on lipid levels in various types of dyslipidemia. Implement appropriate dyslipidemia management during menopause transition Session VI- Obesity Epidemic Describe the current guidelines on the diagnosis, management and treatment of obesity Discuss current guidelines & recommendations for nutrition & lifestyle interventions in various populations Review the role of various types of physical activity on dyslipidemia and cardiovascular risk Implement strategies that improve patient adherence and compliance CRITERIA FOR SUCCESS Statements of credit will be awarded based on the participant’s attendance at each session and submission of the activity evaluation form. A statement of credit will be available upon completion of an online evaluation/claimed credit form at www.lipid.org/cme. If you have questions about this CME/CE activity, please contact the NLA at [email protected]. Please claim credit by June 17, 2016. For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.net within 4 weeks. COMMERCIAL SUPPORT This activity is supported by educational grants from Alexion Pharmaceuticals, Inc., Amarin Pharma Inc., AstraZeneca LP, Merck Sharp & Dohme Corp., & Pfizer. CREDIT DESIGNATION CME credit provided by the National Lipid Association The National Lipid Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The National Lipid Association designates this live activity for a maximum of 18 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in this activity. Physician Assistants NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. Dietitians The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 18 continuing professional education units (CPEUs) for completion of this program/ materials. CDR Accredited Provider #NL002. American Academy of Family Physicians This Live activity, 2016 Annual Scientific Sessions- New Orleans, with a beginning date of 05/19/2016, has been reviewed and is acceptable for up to 13.25 Elective credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity. CE Credit provided by Postgraduate Institute for Medicine Pharmacists Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Session I- Universal Activity Number 0809-9999-16-130-L01-P (Application) Postgraduate Institute for Medicine designates this continuing education activity for 2.25 contact hour(s) (.225 CEUs) of the Accreditation Council for Pharmacy Education Keynote I- Universal Activity Number 0809-9999-16-131-L01-P (Knowledge) Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (.10 CEUs) of the Accreditation Council for Pharmacy Education Session II – Universal Activity Number 0809-9999-16-132-L01-P (Knowledge) Postgraduate Institute for Medicine designates this continuing education activity for 1.75 contact hour(s) (.175 CEUs) of the Accreditation Council for Pharmacy Education Clinical Lipidology Breakout– Universal Activity Number 0809-9999-16-133-L01-P (Knowledge) Postgraduate Institute for Medicine designates this continuing education activity for 2.50 contact hour(s) (.250 CEUs) of the Accreditation Council for Pharmacy Education Basic Science Breakout – Universal Activity Number 0809-9999-16-016-134-P (Knowledge) Postgraduate Institute for Medicine designates this continuing education activity for 2.75 contact hour(s) (.275 CEUs) of the Accreditation Council for Pharmacy Education Keynote II – Universal Activity Number 0809-9999-16-135-L01-P (Knowledge) Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (.10 CEUs) of the Accreditation Council for Pharmacy Education Session III – Universal Activity Number 0809-9999-16-136-L01-P (Knowledge) Postgraduate Institute for Medicine designates this continuing education activity for 2.0 contact hour(s) (.20 CEUs) of the Accreditation Council for Pharmacy Education Session IV – Universal Activity Number 0809-9999-16-137-L01-P (Knowledge) Postgraduate Institute for Medicine designates this continuing education activity for 1.75 contact hour(s) (.175 CEUs) of the Accreditation Council for Pharmacy Education Session V – Universal Activity Number 0809-9999-16-138-L01-P (Knowledge) Postgraduate Institute for Medicine designates this continuing education activity for 1.75 contact hour(s) (.175 CEUs) of the Accreditation Council for Pharmacy Education Keynote III – Universal Activity Number 0809-9999-16-139-L01-P (Knowledge) Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (.10 CEUs) of the Accreditation Council for Pharmacy Education Session VI HIV/AIDS – Universal Activity Number 0809-9999-16-140-L01-P (Application) Postgraduate Institute for Medicine designates this continuing education activity for 2.0 contact hour(s) (.20 CEUs) of the Accreditation